Compare KDP & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KDP | IQV |
|---|---|---|
| Founded | 1981 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8B | 35.1B |
| IPO Year | 2007 | 2013 |
| Metric | KDP | IQV |
|---|---|---|
| Price | $30.79 | $240.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $32.27 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 12.4M | 1.4M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ 45.71 | 4.67 |
| EPS | 0.24 | ★ 1.61 |
| Revenue | ★ $16,603,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $58.73 | $6.77 |
| Revenue Next Year | $14.29 | $5.89 |
| P/E Ratio | ★ $126.17 | $149.84 |
| Revenue Growth | 8.16 | ★ 41.60 |
| 52 Week Low | $24.88 | $154.50 |
| 52 Week High | $35.94 | $251.36 |
| Indicator | KDP | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 64.22 |
| Support Level | $29.78 | $222.95 |
| Resistance Level | $31.91 | $247.52 |
| Average True Range (ATR) | 0.98 | 7.13 |
| MACD | 0.07 | -0.72 |
| Stochastic Oscillator | 50.17 | 81.64 |
Keurig Dr Pepper was established in 2018 following a merger between Keurig Green Mountain Coffee and Dr Pepper Snapple. The company manufactures and distributes coffee systems (including coffee brewers and single-serve coffee pods) under the Keurig and Green Mountain brands, as well as ready-to-drink beverages including flavored (non-cola) sparkling soft drinks under well-known brands such as Dr Pepper, Snapple, and Canada Dry. On Aug. 25, 2025, the firm announced a definitive agreement to acquire coffeemaker JDE Peet's for $18 billion in cash, with the deal now scheduled to close in April 2026. Following the merger, it plans to split into two US-listed entities to focus on refreshment beverages in North America and global coffee separately.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.